Luana R. C. Pesco Koplowitz, M.D., Ph.D., Founder, President and Chief Scientific Officer of DUCK FLATS Pharma commented, “It is rewarding to engage with Oragenics on overall development strategy for ...

Build Audi Skysphere for daughter with all the love of a father (English sub) The Audi skysphere concept shows how the brand ...

Q4 2025 earnings call insights: 2026 guidance, capex cuts, MVC-protected revenue, free cash flow growth & distributions—read now.

Hyperscale Data's objective remains to place up to $100 million of Bitcoin on its balance sheet over time. Consistent with ...

The UPBEAT (c) clinical trial is a multicenter, open-label Phase 1/2 clinical trial designed to evaluate the safety, tolerability, pharmacodynamics, and preliminary efficacy of AFTX-201 in adults with ...

Rabat Business School’s main campus in Morocco. The school is part of the International University of Rabat and serves as a ...

Daniel Kirby, Chief Commercial Officer of Iovance, stated, "The real world Amtagvi data with impressive response rates, paired with unprecedented five-year durability and survival data, demonstrate a ...

Q4 2025 Earnings Call February 6, 2026 8:30 AM ESTCompany ParticipantsJoanne Freiberger - Senior VP of Investor Relations ...

Orion Group Holdings, Inc. (NYSE: ORN) (the “Company” or “Orion”), a leading specialty construction company, today announced that it has acquired J. E. McAmis, Inc. and JEM Marine Leasing LLC ...

Envista Holdings Corp (NYSE:NVST) Q4 2025 Earnings Call Transcript February 6, 2026 Operator: Hello. My name is Vanessa, and ...

Reported fourth-quarter 2025 earnings per share of $1.17 and adjusted earnings per share of $1.02. -- Provided 2026 guidance, including full-year capital expenditures of approximately $12 billion and ...

OPKO Health, Inc.  (NASDAQ: OPK), through its wholly owned subsidiary, OPKO Biologics (OPKO), and Entera Bio Ltd. (NASDAQ: ENTX) (Entera or the Company), a leader in the development of oral peptide ...